CEPI (Coalition for Epidemic Preparedness Innovations)

CEPI (Coalition for Epidemic Preparedness Innovations)
Name	Coalition for Epidemic Preparedness Innovations
Abbreviation	CEPI
Formation	2017
Founders	Gavi, the Vaccine Alliance, Bill & Melinda Gates Foundation, Wellcome Trust, Governments of Norway, Japan
Headquarters	Oslo
Region served	Global

CEPI (Coalition for Epidemic Preparedness Innovations) is an international public-private partnership created to finance and coordinate the development of vaccines against emerging infectious diseases. Operating at the intersection of Gavi, the Vaccine Alliance, World Health Organization, Bill & Melinda Gates Foundation, Wellcome Trust, and multiple national funders such as the Government of Norway and the Government of Japan, it seeks to accelerate vaccine development for priority pathogens and ensure equitable access during outbreaks.

Overview and Mission

CEPI's stated mission focuses on advancing vaccine candidates for priority pathogens identified by the World Health Organization and preparing platforms for rapid response to novel threats such as novel coronaviruses. Its strategic objectives align with global health architecture actors including Gavi, the Vaccine Alliance, Coalition for Epidemic Preparedness Innovations partners, National Institutes of Health, European Commission, United States Department of Health and Human Services, and regional bodies like the Africa Centres for Disease Control and Prevention. The organization emphasizes the development of platform technologies, stockpiling, and equitable allocation mechanisms coordinated with COVAX Facility, G7, G20, and other multilateral initiatives.

History and Governance

CEPI was launched following calls from stakeholders after outbreaks including the 2014–2016 West African Ebola epidemic and was announced at gatherings attended by figures from World Economic Forum, Bill & Melinda Gates Foundation, and heads of state from Norway and India. Its governance structure includes a Board composed of representatives from donor countries such as United Kingdom, Norway, Japan, Germany, and institutions like Wellcome Trust, Gavi, the Vaccine Alliance, and the World Health Organization. The Secretariat operates from Oslo with scientific advisory input from panels including experts formerly associated with National Institutes of Health, European Medicines Agency, London School of Hygiene & Tropical Medicine, Harvard School of Public Health, and leading vaccine developers such as Moderna, Pfizer, and AstraZeneca.

Funding and Partnerships

Funding for CEPI has come from philanthropic organizations like the Bill & Melinda Gates Foundation and Wellcome Trust, sovereign donors including the Government of Norway, Government of Japan, Government of Germany, Government of the United Kingdom, and multinational entities such as the European Commission and multilateral initiatives tied to the World Bank. CEPI forms partnerships with biotechnology firms including Moderna, Inovio Pharmaceuticals, CureVac, Novavax, and academic institutions like University of Oxford, University of Tokyo, University of Cambridge, and Karolinska Institutet. It coordinates with procurement and delivery partners such as Gavi, the Vaccine Alliance and regulatory authorities including the European Medicines Agency and the U.S. Food and Drug Administration.

Research and Development Programs

CEPI invests in vaccine platforms—mRNA, viral vectors, protein subunit, and self-amplifying RNA—through collaborations with companies like Moderna, BioNTech, AstraZeneca, Novavax, and research centers including Salk Institute and Institut Pasteur. Programs target pathogens on the WHO R&D Blueprint such as Ebola virus disease 2014–2016 West African Ebola epidemic, Lassa fever, MERS-CoV, and Nipah virus, and it has supported candidate vaccines developed at institutions like University of Oxford and National Institutes of Health. CEPI also funds preclinical and clinical trial networks, manufacturing scale-up with partners in India and Brazil, and regulatory science projects involving the European Medicines Agency and the World Health Organization.

Pandemic Preparedness and Response Efforts

During the COVID-19 pandemic, CEPI played a role in funding rapid vaccine development efforts alongside Operation Warp Speed, COVAX Facility, and national research initiatives such as those funded by the National Institutes of Health and Horizon 2020. CEPI-supported candidates advanced through phases of clinical trials coordinated with trial sites in South Africa, Brazil, United Kingdom, and United States. The organization also engaged with logistics and distribution partners including Gavi, the Vaccine Alliance and national immunization programs in countries like India and Indonesia to plan equitable access. CEPI’s platform investments aim to shorten timelines for first-in-human trials for future novel pathogens, linking with surveillance networks run by World Health Organization and regional public health institutions such as the Africa Centres for Disease Control and Prevention.

Criticism and Controversies

CEPI has faced scrutiny over issues including intellectual property and access conditions attached to funded projects, prompting debate among stakeholders such as Médecins Sans Frontières, The Lancet, and policy groups in United Kingdom and United States. Critics from civil society and some academic commentators affiliated with King’s College London and University of Oxford have raised concerns about transparency in grant agreements and the balance between incentivizing private partners like Moderna and ensuring affordable global access. Questions have been posed in parliamentary inquiries in Norway and policy analyses by think tanks in Brussels and Washington, D.C. regarding governance, prioritization of pathogens, and reliance on specific technology platforms.

Category:Vaccination